Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2Aantagonism

The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions

(2012) Jessica L. Santerre et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

The genetics of antipsychotic induced tremors: A genome-wide pathway analysis on the STEP-BD SCP sample

(2011) Antonio Drago et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats

(2011) Andrew R. Brown et al.   EXPERIMENTAL NEUROLOGY

Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease

(2011) Lyndsey E. Collins et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity

(2010) Lyndsey E. Collins et al.   BEHAVIOURAL BRAIN RESEARCH

Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies

(2010) Catherine J. Wei et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Cognitive change on the repeatable battery of neuropsychological status (RBANS) in parkinson's disease with and without bilateral subthalamic nucleus deep brain stimulation surgery

(2010) Eric Rinehardt et al.   CLINICAL NEUROPSYCHOLOGIST

A functionally relevant and long-term model of deep brain stimulation of the rat subthalamic nucleus: advantages and considerations

(2010) A. L. Spieles-Engemann et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia

(2010) Meaghan Creed et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease

(2010) Elena Moro et al.   MOVEMENT DISORDERS

Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease

(2010) Christine Daniels et al.   MOVEMENT DISORDERS

Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors

(2010) A.M. Farrar et al.   NEUROSCIENCE

The different performance among motor tasks during the increasing current intensity of deep brain stimulation of the subthalamic nucleus in rats with different degrees of the unilateral striatal lesion

(2010) Xin Fang et al.   NEUROSCIENCE LETTERS

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats

(2010) Hideto Miwa et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Activation of the NMDA receptor involved in the alleviating after-effect of repeated stimulation of the subthalamic nucleus on motor deficits in hemiparkinsonian rats

(2009) Hisanao Akita et al.   BRAIN RESEARCH

Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition

(2009) Hai-Ying Shen et al.   Current Neuropharmacology

Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease

(2009) Annalisa Pinna   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

(2009) Annalisa Pinna et al.   NEUROPHARMACOLOGY

Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide

(2009) A.J. Betz et al.   NEUROSCIENCE

Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX

(2009) Lyndsey E. Collins et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors

(2008) S. Ferre et al.   CURRENT PHARMACEUTICAL DESIGN

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

(2008) John et al.   Frontiers in Bioscience-Landmark

The clinical significance of neuropsychological changes following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease

(2008) Christopher I. Higginson et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease

(2008) J Grace et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Dopamine/adenosine interactions related to locomotion and tremor in animal models: Possible relevance to parkinsonism

(2008) John D. Salamone et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2A receptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801

(2007) Geanne M.A. Cunha et al.   EXPERIMENTAL NEUROLOGY

Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies

(2007) Reinaldo Naoto Takahashi   Frontiers in Bioscience-Landmark

Tremor dominant parkinsonism: Clinical description andLRRK2 mutation screening

(2007) Jordi Clarimón et al.   MOVEMENT DISORDERS

Paradoxes of functional neurosurgery: Clues from basal ganglia recordings

(2007) Peter Brown et al.   MOVEMENT DISORDERS